Wilmington Pharmaceuticals

At Wilmington Pharmaceuticals, we evolve and out-license patient-friendly, fast-dissolving formulations for founded medicines. We reach FDA approval and rapid commercialization for our licensing partners, minimizing regulatory risk while maximizing economic opportunity. Our points of differentiation supply you with an perfect development partner. We exclusively license Catalent Pharma Solutions' Zydis technology for use in Metozolv ODT (metoclopramide) and our current development products in pain and the central nervous system.